Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

41,824 stories, page 470 of 698

Advanced search

🇺🇸Jul 21Industryinvestors.abeonatherapeutics.comTier 1 · Company source

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona TherapeuticsOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Jasper and Kira merge to build immune-focused biotech

pharmaphorumOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw

Investing.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Summer registration exam pass rate highest since 2021

The Pharmaceutical JournalOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Biotech Executes Definitive License Agreement

GlobeNewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

The Manila TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange

Yahoo Finance UKOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong

Fierce BiotechOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trial

Kalkine MediaOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

South China Morning PostOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

PR NewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PBS Biotech Wins 2026 Cell Products Development of the Year Award

PR NewswireOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License

Stock TitanOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Compugen to Hold 1x1 Meetings at July 28-29 BTIG Event

Stock TitanOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer

PR NewswireOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Novartis Q2 profits recover as revenue mantle passes to newer medicines

Pharmaceutical TechnologyOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Shaanxi Kanghui Pharmaceutical's Unit Signs Computing Power Service Contract

TradingViewOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

AAIC26: Alzheimer’s disease heterogeneity calls for a rethink

Pharmaceutical TechnologyOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom

Bloomberg.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

Life Sciences IP ReviewOriginal source

🇺🇰Jul 21Industrygsk.comTier 1 · Company source

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

GSK NewsOriginal source

🌍Jul 21discoverynews.google.comTier 2 · Trade media

Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory

Pharmaceutical TechnologyOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

2026 Changping Medical & Healthcare Financial Investment Innovation Forum: Integrating Industry Wisdom, Forging Trend-Driven Innovation

36 KrOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss

TrefisOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event

Stock TitanOriginal source

🇺🇸Jul 21Researchpubmed.ncbi.nlm.nih.govTier 1 · Research record

Are Radiopharmaceutical Therapy Trials Designed to Undertreat?

PubMed Journal of Clinical Oncology RSSOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Securing Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stage

geneonline.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Swiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Jennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

MarketBeatOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

Bloomberg Law NewsOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Is recalled lettuce safe after false positive result? FDA issues warning

OurQuadCitiesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Kolon TissueGene's TG-C Misses Primary Endpoint in U.S. Trial; Stock Hits Limit Down, Approval Timeline Disrupted

finance.biggo.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Enterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527

TradingViewOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

HLB Therapeutics completes patient enrollment in global phase 3 trial of RGN-259 for neurotrophic keratitis

더바이오Original source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Citizens initiates Annexon stock with underperform on GA trial concerns

Investing.comOriginal source

🇺🇰Jul 21Regulatorygov.ukTier 1 · Regulatory source

Respiratory virus circulation: England and Wales

Data showing the seasonality of major respiratory viruses.

UK Health Security AgencyOriginal source

🇺🇰Jul 21Regulatorygov.ukTier 1 · Regulatory source

Rabies: risk assessment, post-exposure treatment, management

Guidance on assessing risk following rabies exposure, post-exposure treatment, and public health man...

UK Health Security AgencyOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Maharashtra FDA chief widens crackdown on food adulteration, fake drugs

Business StandardOriginal source

🇫🇷Jul 21Researchchru-strasbourg.frTier 2 · Direct publisher

Centre de vaccinations internationales : un accompagnement personnalisé avant le départ

Hôpitaux Universitaires de StrasbourgOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

AI healthcare company acquires US biotech firm for USD 1.7bn

medwatch.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Kolon TissueGene's TG-C Fails U.S. Phase 3 Efficacy Trial

조선일보Original source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

One of Europe's most advanced biotech campuses is in Marburg — and it's looking for pioneers

Labiotech.euOriginal source

🇯🇵Jul 21Deviceshoya.comTier 1 · Company source

公正取引委員会からの勧告について

HOYA MedicalOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Bias and fairness in AI drug discovery: What it means for who benefits from new medicines

Drug Discovery NewsOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Atea Completes Enrollment in Phase 3 Hepatitis C Trial Evaluating Bemnifosbuvir and Ruzasvir

Infection Control TodayOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Citizens initiates Annexon stock with underperform on GA trial concerns

Investing.com UKOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

4D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMD

The Clinical Trial VanguardOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

OMEICOS’ OMT-28 Advances to Phase 3 Trial in Mitochondrial Disease

The Clinical Trial VanguardOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter

Proactive financial newsOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter

Proactive financial newsOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Co-CEO of Kolon TissueGene, Jeon Seung-ho, claimed that the results of the first phase 3 clinical tr..

매일경제Original source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Regional pharmaceutical initiative awarded $16M in federal funds for medicine production

Richmond BizSenseOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

5 Retatrutide Side Effects: What We Know From Clinical Trials

RoOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders

markets.businessinsider.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Trump purge at FDA and USDA triggers food safety ‘brain drain’

FoodNavigator.comOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Biotech deals surge to record as fear of missing out grips Big Pharma

Financial TimesOriginal source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Kolon TissueGene stumbles in US phase 3 as placebo surges, pins FDA hopes on next trial - CHOSUNBIZ

ChosunbizOriginal source

🇫🇷Jul 21Industryinnate-pharma.comTier 1 · Company source

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from...

Innate Pharma (IR)Original source

🌍Jul 21discoverynews.google.comTier 3 · Aggregated media

Chemical and pharmaceutical industry: half-year results for 2026 show continuing crisis

European CoatingsOriginal source

Pharmaceutical industry news

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Jasper and Kira merge to build immune-focused biotech

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw

Summer registration exam pass rate highest since 2021

PharmAla Biotech Executes Definitive License Agreement

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange

‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong

OKYO Pharma Chairman Gabriele Cerrone Boosts Stake to 20.51% with $35,000 Share Acquisition Ahead of Phase 3 Trial

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

PBS Biotech Wins 2026 Cell Products Development of the Year Award

PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License

Compugen to Hold 1x1 Meetings at July 28-29 BTIG Event

Altesa BioSciences Welcomes Seasoned Biotech Leader Brett Haumann, MBBCh, MBA as Chief Executive Officer

Novartis Q2 profits recover as revenue mantle passes to newer medicines

Shaanxi Kanghui Pharmaceutical's Unit Signs Computing Power Service Contract

AAIC26: Alzheimer’s disease heterogeneity calls for a rethink

US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom

Arbutus takes Comirnaty LNP patent fight to Canada and UPC

ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026

Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory

2026 Changping Medical & Healthcare Financial Investment Innovation Forum: Integrating Industry Wisdom, Forging Trend-Driven Innovation

Ultragenyx Pharmaceutical Stock Extends A 9-Day Losing Streak To A 20% Loss

Alterity Therapeutics (NASDAQ: ATHE) to meet investors at BTIG biotech event

Are Radiopharmaceutical Therapy Trials Designed to Undertreat?

Securing Global Pharmaceutical Supply Chains: Strategic Redundancy, Local Manufacturing, and Reimbursement Reform Take Center Stage

Swiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Jennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules

Is recalled lettuce safe after false positive result? FDA issues warning

Kolon TissueGene's TG-C Misses Primary Endpoint in U.S. Trial; Stock Hits Limit Down, Approval Timeline Disrupted

Enterprise value to EBIT forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527

﻿﻿HLB Therapeutics completes patient enrollment in global phase 3 trial of RGN-259 for neurotrophic keratitis

Citizens initiates Annexon stock with underperform on GA trial concerns

Respiratory virus circulation: England and Wales

Rabies: risk assessment, post-exposure treatment, management

Maharashtra FDA chief widens crackdown on food adulteration, fake drugs

Centre de vaccinations internationales : un accompagnement personnalisé avant le départ

AI healthcare company acquires US biotech firm for USD 1.7bn

Kolon TissueGene's TG-C Fails U.S. Phase 3 Efficacy Trial

One of Europe's most advanced biotech campuses is in Marburg — and it's looking for pioneers

公正取引委員会からの勧告について

Bias and fairness in AI drug discovery: What it means for who benefits from new medicines

Atea Completes Enrollment in Phase 3 Hepatitis C Trial Evaluating Bemnifosbuvir and Ruzasvir

Citizens initiates Annexon stock with underperform on GA trial concerns

4D Molecular Therapeutics Reports 2-Year Durability Data for 4D-150 in Wet AMD

OMEICOS’ OMT-28 Advances to Phase 3 Trial in Mitochondrial Disease

Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter

Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter

Co-CEO of Kolon TissueGene, Jeon Seung-ho, claimed that the results of the first phase 3 clinical tr..

Regional pharmaceutical initiative awarded $16M in federal funds for medicine production

5 Retatrutide Side Effects: What We Know From Clinical Trials

Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders

Trump purge at FDA and USDA triggers food safety ‘brain drain’

Biotech deals surge to record as fear of missing out grips Big Pharma

Kolon TissueGene stumbles in US phase 3 as placebo surges, pins FDA hopes on next trial - CHOSUNBIZ

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

Chemical and pharmaceutical industry: half-year results for 2026 show continuing crisis

HLB Therapeutics completes patient enrollment in global phase 3 trial of RGN-259 for neurotrophic keratitis